Innovative Oncology Platform Palleon Pharmaceuticals has developed a proprietary Convergence Platform leveraging glycoscience and immunology to create Glyco-Immune Checkpoint inhibitors, presenting a unique opportunity to collaborate on advanced cancer immunotherapies and expand into personalized treatment solutions.

Growing Pipeline and Funding With a pipeline consisting of next-generation immuno-oncology agents and a recent Series A funding of 47.6 million dollars, Palleon is actively seeking strategic partners and investors to accelerate clinical development and corporate growth in oncology and related therapeutic areas.

Strategic Collaborations Recent partnerships, including asset sales and co-development agreements with biotech firms like Henlius, highlight opportunities to engage in joint development projects, licensing agreements, or distribution partnerships across key markets, especially in China.

Leadership and Expertise Led by experienced scientists and recently strengthened by new board members and executive hires, Palleon presents a compelling opportunity to access innovative scientific expertise and strategic alliances that can support market expansion and technological advancements.

Market Expansion Potential While primarily focused on oncology, Palleon’s platform has applications in infectious diseases, neurodegeneration, inflammation, and fibrosis, providing diverse opportunities to develop or commercialize new therapeutic solutions in high-growth, underserved markets.